Research
Hormonal
Tirzepatide use, particularly with unsupervised dose escalation and caloric restriction, can cause euglycemic ketoacidosis (EKA) in non-diabetic patients.
If you are using tirzepatide, do not self-prescribe or self-escalate doses. Monitor for signs of metabolic acidosis (nausea, vomiting, abdominal pain, fatigue) especially if you are eating very little. Seek immediate medical attention if these symptoms occur, as they can signal euglycemic ketoacidosis, a rare but serious condition.
WeakSupportsLOW confidence
This case highlights EKA as a rare but potentially serious adverse effect of tirzepatide, particularly in the context of appetite suppression and caloric restriction.
Why this rating
Based on a single case report (Level 4 evidence), lacking controlled trials or cohort data.
Source
Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale
Renisha Singh · Cureus · 2025
DOI 10.7759/cureus.83187
case_report · n=1Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →